# FuSion (Fudan and Singlera pan-cancer screening cohort)

Source: https://onco.cc/trials/fusion-singlera/  
OnCo record `fusion-singlera` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese cohort of up to 60,000 people built by Fudan University and Singlera to develop a blood test for many cancers.

## Summary

FuSion (NCT05159544) is an observational study sponsored by Singlera Genomics Inc with Fudan University. It evaluates sensitivity, specificity and predictive values of a screening model developed by Fudan University and Singlera in a two-year follow-up cohort, and develops a multi-omic model in a community cohort.

The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 17 April 2024), with an estimated 60,000 participants, a start on 6 July 2021 and primary completion expected on 6 July 2024.

## Fields

- Kind: Trial
- Last checked: 2026-10-29
- Also known as: FuSion Program
- Registry id: NCT05159544
- Phase: observational
- Setting: Chinese adults in routine health checks and community cohorts, followed to develop and test a multi-omic pan-cancer screening model
- Sponsor: Singlera Genomics Inc. with Fudan University
- Enrolled: 60000

## Sources

- ClinicalTrials.gov NCT05159544: https://clinicaltrials.gov/study/NCT05159544

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- companies: [Singlera Genomics](https://onco.cc/companies/singlera/)
- drugs: [PanSeer](https://onco.cc/drugs/panseer/)

---
JSON: https://onco.cc/api/v1/entities/fusion-singlera.json